Proactive Investors - Run By Investors For Investors

Cellmid director shows faith in life sciences company through on-market trades

Bruce Gordon has acquired two batches of shares recently with a total value of almost $13,300.
Australian currency
The company has lead programs in multiple disease indications

Cellmid Limited (ASX:CDY) non-executive director Bruce Gordon continues to demonstrate his confidence in the life sciences company through on-market share purchases.

Gordon has acquired a further 8,684 shares valued at almost $3,300 and now holds 110,000 shares in an indirect interest.

Last week’s acquisition follows a recent purchase of more than 26,000 shares valued at $10,000.

READ: Cellmid gains new substantial shareholder as director increases his interest to 6.4%

Other company directors have also been acquiring shares recently in a variety of ways, including on-market trades and participation in the recent share placement and share purchase plan.
US-based non-executive director Dennis Eck is a substantial shareholder with a 6.4% interest after acquiring a further batch of shares valued at $1 million.

Managing director and CEO Maria Halasz acquired shares valued at $100,000 while non-executive director Dr Martin Cross has made purchases valued at $50,400.

READ: Cellmid driving towards profitability with anti-ageing product range

Cellmid is an Australian life sciences accelerator with lead programs in multiple disease indications.

The company holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. 

Cellmid, through wholly-owned subsidiaries Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart and hair loss.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

skin cream
October 25 2018
The cream is currently undergoing its first-in-human studies, with researchers assessing its skin irritancy, moisturisation potential and skin barrier function
porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use